Safety and Effectiveness of Regorafenib in Routine Clinical Practice Setting

Study Objective

The primary objective of this study is to further characterize safety of regorafenib use in routine clinical practice settings.
The secondary objective of this study is to assess the effectiveness of regorafenib in routine clinical practice settings as measured by OS, Progression Free Survival (PFS) and Disease control rate (DCR). Health Related Quality of Life (HRQoL) Data will be collected in applicable countries. Furthermore health care resource utilization will be captured.

Participation conditions

Inclusion criteria:

 Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator’s routine treatment practice to prescribe regorafenib.
 Availability of a signed informed consent

Exclusion criteria

 Patients participating in an investigational program with interventions outside of routine clinical practice

Centre Hospitalier du Luxembourg
Centre Hospitalier Emile Mayrisch (CHEM)